KAPA · Kairos Pharma, LTD. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-10-08 | Singhvi Rahul |
Director |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. Consists of 49,204 RSUs which remain subject to vesting. |
COMMON STOCK
|
19,084 |
| 2025-10-08 | Murali Ramachandran |
VP of Research and Development |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date. Consists of (1) 142,191 shares of common stock and (2) 157,338 RSUs which remain subject to vesting. |
COMMON STOCK
|
152,672 |
| 2025-10-08 | Samuelson Doug |
Chief Financial Officer |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date. Consists of (1) 140,367 shares of common stock and (2) 152,672 RSUs which remain subject to vesting. |
COMMON STOCK
|
152,672 |
| 2025-10-08 | Bhowmick Neil |
Chief Scientific Officer |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 171,756 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 171,756 RSUs are scheduled to vest on the on the first anniversary of the grant date which is October 8, 2026. Consists of (1) 1,135,317 shares of common stock and (2) 176,422 RSUs which remain subject to vesting. |
COMMON STOCK
|
171,756 |
| 2025-10-08 | Keyoung Hansoo Michael |
Director |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting. |
COMMON STOCK
|
19,084 |
| 2025-10-08 | Bae Hyun W. |
Director |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 19,084 RSUs issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. Consists of (i) 54,286 shares of common stock and (ii) 19,084 RSUs which remain subject to vesting. |
COMMON STOCK
|
19,084 |
| 2025-10-08 | Yu John S |
Director, CEO and Chairman, 10% Owner |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date. Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting. |
COMMON STOCK
|
190,840 |
| 2025-09-16 | Keyoung Hansoo Michael |
Director |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO. Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting. |
COMMON STOCK
|
10,000 |
| 2025-09-16 | Bae Hyun W. |
Director |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and vest annually in three substantially equal installments commencing on the anniversary date of the IPO. Consists of (i) 47,620 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting. |
COMMON STOCK
|
10,000 |
| 2025-01-01 | Murali Ramachandran |
VP of Research and Development |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof. Consists of (1) 137,724 shares of common stock and (2) 9,333 RSUs which remain subject to vesting. |
COMMON STOCK
|
14,000 |
| 2025-01-01 | Yu John S |
Director, CEO and Chairman, 10% Owner |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof. Consists of (1) 5,346,504 shares of common stock and (2) 9,334 RSUs which remain subject to vesting. |
COMMON STOCK
|
14,000 |
| 2025-01-01 | Bhowmick Neil |
Chief Scientific Officer |
Award↑
Filing footnotes — COMMON STOCK (Direct)
Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof. Consists of (1) 1,130,650 shares of common stock and (2) 9,333 RSUs which remain subject to vesting. |
COMMON STOCK
|
14,000 |
| 2024-11-25 | Murali Ramachandran |
VP of Research and Development |
Buy↑
|
COMMON STOCK
|
200 |
| 2024-11-22 | Samuelson Doug |
Chief Financial Officer |
Buy↑
|
COMMON STOCK
|
2,500 |
| 2024-11-20 | Yu John S |
Director, CEO and Chairman, 10% Owner |
Buy↑
|
COMMON STOCK
|
4,000 |